phrykt

OnKure Therapeutics, Inc. (OKUR): who owns it and who trades it

As of Nov 16, 2026, OKUR insiders reported 8 open-market sales worth $5.6K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason A. Leverone (CFO), with $4.4K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling OnKure Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns OKUR

76 funds and institutions reported OKUR shares worth $160M at the end of Q2 2026, about 86% of the company. The largest holder is Ra Capital Management, L.P. with 9.9%.

Funds and institutions (13F) 86%Everyone else 14%

10 largest owners, by share of the company

Ra Capital Management, L.P.9.9%
Bvf Inc8.0%
Acorn Capital Advisors, LLC7.0%
StepStone Group LP6.6%
ADAR1 Capital Management, LLC5.5%
Vivo Capital, LLC4.8%
Vestal Point Capital, LP4.5%
BlackRock, Inc.3.7%
Trails Edge Capital Partners, LP3.6%
Vanguard Capital Management LLC3.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.4.00M9.87%$18.2MNo change
Bvf Inc3.24M7.99%$14.8M+64%
Acorn Capital Advisors, LLC2.84M7.01%$12.9MNo change
StepStone Group LP2.66M6.57%$12.1MNo change
ADAR1 Capital Management, LLC2.24M5.53%$10.2M-8%
Vivo Capital, LLC1.93M4.76%$8.8MNo change
Vestal Point Capital, LP1.83M4.51%$8.3M-1%
BlackRock, Inc.1.50M3.70%$6.8M+2925%
Trails Edge Capital Partners, LP1.44M3.55%$6.6MNew
Vanguard Capital Management LLC1.44M3.55%$6.6M+147%
Adage Capital Partners Gp, L.l.c.1.20M2.97%$5.5MNo change
Citadel Advisors LLC1.19M2.93%$5.4M+3058%
Sio Capital Management, LLC1.08M2.66%$4.9MNo change
Prosight Management, LP978,9922.42%$4.5M-55%
Logos Global Management LP963,8552.38%$4.4MNew
Geode Capital Management, LLC724,4381.79%$3.3M+634%
NEA Management Company, LLC478,5481.18%$2.2MNo change
State Street Corp463,6621.14%$2.1M+3344%
Ensign Peak Advisors, Inc431,6311.07%$2MNew
Renaissance Technologies LLC358,7380.89%$1.6M-5%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, OKUR insiders reported $0 of open-market purchases and $5.6K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$5.6K
8 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 21, 2026
Filed Sep 23, 2026

Purchases and sales by month

$1.7K$1.7KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 21, 2026Nicholas A SaccomanoCEOSale87$2.97$258Form 4
Sep 21, 2026Jason A. LeveroneCFOSale302$2.97$897Form 4
Jun 22, 2026Nicholas A SaccomanoCEOSale86$4.40$378Form 4
Jun 22, 2026Jason A. LeveroneCFOSale303$4.40$1.3KForm 4
Mar 23, 2026Nicholas A SaccomanoCEOSale86$4.16$358Form 4
Mar 23, 2026Jason A. LeveroneCFOSale301$4.16$1.3KForm 4
Dec 22, 2025Nicholas A SaccomanoCEOSale87$2.97$258Form 4
Dec 22, 2025Jason A. LeveroneCFOSale302$2.97$897Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jason A. LeveroneChief Financial Officer–$4.4KSep 21, 2026
Nicholas A SaccomanoPresident and CEO, Director–$1.3KSep 21, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

OKUR short interest

Low short interest. 3.2% of OKUR shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went up 551%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.30M OKUR shares were sold short, 3.2% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 306,010 shares, buying them all back would take about 4.2 trading days (days to cover).

Shares short, % of all shares

3.21%May 15Oct 309.76%

Days to cover

4.2May 15Oct 3012.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.30M3.21%-6%306,0104.2
Oct 15, 20261.39M3.42%+13%543,5012.5
Sep 30, 20261.22M3.02%-11%257,0744.8
Sep 15, 20261.38M3.40%+4%148,2149.3
Aug 31, 20261.32M3.26%+23%171,7647.7
Aug 14, 20261.07M2.65%-10%134,8058.0
Jul 31, 20261.19M8.68%+0%112,26310.6
Jul 15, 20261.18M8.64%+34%204,0255.8
Jun 30, 2026878,6686.43%+211%755,7931.2
Jun 15, 2026282,4002.07%+20%379,7741.0
May 29, 2026234,9311.72%+18%216,2461.1
May 15, 2026199,3921.46%+93%142,1741.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

OnKure Therapeutics company events

OnKure Therapeutics filed 7 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 13, 2026LeadershipThe Board of Directors of OnKure Therapeutics, Inc. approved an option repricing. Filing
  3. Aug 4, 2026ResultsReleased financial results. Filing
  4. Jun 4, 2026LeadershipOnKure Therapeutics, Inc. amended and restated its 2024 Equity Incentive Plan, effective as of June 3, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below). Filing
  5. May 5, 2026ResultsReleased financial results. Filing
  6. Mar 30, 2026LeadershipIn connection with the Private Placement, the Board elected Dr. Liam Ratcliffe as a Class I director of the Company, effective and contingent on the closing of the Private Placement. Filing
  7. Mar 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

OnKure Therapeutics financials

Famous investors that hold OKUR

2 of the 50 well-known investors we track reported holding OKUR in their latest 13F filing. The largest position is Ken Griffin's, worth $1.5M.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026556,493$1.5M0.0%-53%
Jim Simons · Renaissance TechnologiesQ3 2026353,150$962K0.0%-2%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named OKUR in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A5.2%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A5.2%
Oct 7, 2026Coastlands Capital LP13G6.7%
Oct 7, 2026Coastlands Capital LP13G6.7%

Questions about OnKure Therapeutics, Inc. (OKUR) stock

Who owns the most OKUR stock?

The largest reported owner of OnKure Therapeutics, Inc. (OKUR) is Ra Capital Management, L.P., with 9.9% of the company. In total, 76 funds and institutions reported holding OKUR at the end of Q2 2026, together about 86% of the shares. See the largest owners.

Are OKUR insiders buying or selling?

In the last 12 months, OKUR insiders reported no open-market purchases and 8 sales worth $5.6K. The latest trade was on Sep 21, 2026. See every trade.

What is the short interest in OKUR?

As of Oct 30, 2026, 1.30M OKUR shares were sold short, 3.2% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 306,010 shares, buying them all back would take about 4.2 trading days (days to cover). See the history.

Which famous investors hold OKUR?

2 of the 50 well-known investors we track reported OKUR in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $1.5M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.